Gene · 7006
TEC: tec protein tyrosine kinase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TEC: tec protein tyrosine kinase. Genes, record 7006. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7006
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P42680 | Tyrosine-protein kinase Tec | 631 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents47
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 66682 | P42680 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 10794 | P42680 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 10794 | P42680 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 37051 | P42680 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 37051 | P42680 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 37051 | P42680 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 87488 | P42680 | Espacenet |
| US 11351168 B1 | 2022-06-07 | 2 | P42680 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 190459 | P42680 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 11437 | P42680 | Espacenet |
1 to 10 of 47
See all 47 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials24
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07228390 | RITLECITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07226531 | RITLECITINIB | ClinicalTrials.gov | ||
| NCT07200128 | RITLECITINIB | ClinicalTrials.gov | ||
| NCT07152626 | RITLECITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07152119 | RITLECITINIB TOSYLATE | ClinicalTrials.gov | ||
| NCT07029828 | RITLECITINIB | PHASE3 | ClinicalTrials.gov | |
| NCT07029711 | RITLECITINIB | PHASE3 | ClinicalTrials.gov | |
| NCT06873945 | RITLECITINIB | PHASE3 | ClinicalTrials.gov | |
| NCT06573593 | RITLECITINIB | ClinicalTrials.gov | ||
| NCT06531109 | RITLECITINIB | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsNIH grants949
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TEC papers | Newest fiscal year |
|---|---|---|---|
| R01AI043957 | Structural Studies of a T cell Specific Tyrosine Kinase | 23 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 11 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 10 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 9 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 9 | 2025 |
| P01AI091580 | Defining the Unique Properties of the Distinct Signaling Machinery Used by the TCR | 7 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 6 | 2025 |
| R35GM119437 | Dynamics of Ligand Binding and Protein Kinase Regulation | 5 | 2025 |
| ZIAAR041159 | Cytokine Signaling, Immunoregulation and Autoimmune and Immunodeficiency Diseases | 5 | 2025 |
| R01CA177292 | Targeted Therapies for Lymphoid Malignancies | 4 | 2025 |
1 to 10 of 949Source NIH's project files
See all 949 nih grantsPapers1,477
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Engineered multicolor "Fluorescent Lantern" TEC-Fusion protein with tunable spectra enables multiplexed fluorescent labeling and biological imaging. | Spectrochim Acta A Mol Biomol Spectrosc | 2027 | 42632270 | PubTator, text mining | PubMed |
| JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions. | Drug Des Devel Ther | 2026 | 42824469 | PubTator, text mining | PubMed |
| Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study. | Dermatol Ther (Heidelb) | 2026 | 42823604 | PubTator, text mining | PubMed |
| Mechanism and Individualized Management of Hypertension Associated With Bruton Tyrosine Kinase Inhibitors: The PCSK9/Notch3 Signaling Pathway. | Front Biosci (Landmark Ed) | 2026 | 42811994 | PubTator, text mining | PubMed |
| Success of Deuruxolitinib (Leqselvi™) in Extensively Treatment-Resistant Alopecia Universalis: A Case Report. | Cureus | 2026 | 42529366 | PubTator, text mining | PubMed |
| Bruton Tyrosine Kinase as Therapeutic Target in Cardiovascular Diseases-Executive Summary. | Thromb Haemost | 2026 | 42419695 | PubTator, text mining | PubMed |
| Tectorigenin Protects Irradiation-Induced Injury of HUVECs by Inhibiting Mitophagy Through PINK1/Parkin Pathway. | Front Biosci (Landmark Ed) | 2026 | 42216527 | PubTator, text mining | PubMed |
| Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies. | J Enzyme Inhib Med Chem | 2026 | 42212521 | PubTator, text mining | PubMed |
| Site-Specific Phosphoproteomic Profiling of CAV1 Reveals Co-Regulatory Kinase Networks in Cancer Signaling. | Int J Mol Sci | 2026 | 42196307 | PubTator, text mining | PubMed |
| Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. | Dermatol Ther (Heidelb) | 2026 | 42171987 | PubTator, text mining | PubMed |
1 to 10 of 1,477
See all 1,477 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7006
GET https://conductscience.org/api/genes/v1/7006/patents?page=2